

**In the Specification**

Please amend the specification as follows.

Please replace the paragraph on page 10, lines 17-31 with the following amended paragraph.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent 4,554,101 provides that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with a biological property of the protein. As detailed in U.S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine ( $\pm 3.0$ ); aspartate ( $+3.0 \pm 1$ ); glutamate ( $+3.0 \pm 1$ ); ~~seine~~ serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline ( $-0.5 \pm 1$ ); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). As is understood by those skilled in the art, an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent polypeptide. In such changes, the substitution of amino acids whose hydrophilicity values are within  $\pm 2$  of each other is preferred, those which are within  $\pm 1$  of each other are particularly preferred, and those within  $\pm 0.5$  of each other are even more particularly preferred.

Please replace the paragraph on page 114, after the heading "**Abstract Of The Disclosure**," with the following amended paragraph. A separate sheet is attached herewith pursuant to 37 C.F.R. § 1.72.

Mixtures of conjugates in which each conjugate in the mixture comprises a growth hormone drug coupled to an oligomer that includes a polyalkylene glycol moiety wherein the mixtures have a molecular weight distribution with a standard deviation of less than about 22 Daltons are disclosed. Methods of treating growth hormone deficiency in a subject in need of such treatment and methods of accelerating the growth rate of an animal are also disclosed. Processes for synthesizing substantially monodispersed mixtures of conjugates wherein each conjugate comprises a growth hormone drug coupled to an oligomer that comprises a polyethylene glycol moiety are further provided.

In re: Ekwuribe et al.  
Serial No.: 09/873,757  
Filed: June 4, 2001  
Page 3 of 23

**In the Drawings**

Please replace Figures 29 and 30 with the replacement sheets submitted herewith to correct the misspelling of “luciferase” in the y-axis label of these figures.